Match!
Amy L. Phillips
Merck Serono
67Publications
9H-index
289Citations
Publications 67
Newest
Source
Source
#1Maria K. HoutchensH-Index: 17
#2Natalie C. EdwardsH-Index: 2
Last.Amy L. PhillipsH-Index: 9
view all 5 authors...
Objective To compare pregnancy prevalence and complications in women with and without multiple sclerosis (MS). Methods This retrospective US administrative claims study used data from January 1, 2006, to June 30, 2015. All data for women with MS were included. A nationally representative 5% random sample from approximately 58 million women without MS was used to compute the dataset. Annual pregnancy rates, identified via diagnosis/procedure codes and adjusted for covariates, were estimated via l...
4 CitationsSource
#1Maria K. HoutchensH-Index: 17
#2Natalie C. EdwardsH-Index: 2
Last.Amy L. PhillipsH-Index: 9
view all 3 authors...
Objective To evaluate relapse rates and disease-modifying drug (DMD) treatment in US women with multiple sclerosis (MS) and a live birth. Methods This retrospective administrative claims database study used US commercial health plan data from women with MS and a live birth from January 1, 2006, to June 30, 2015. Relapses and DMD treatment were evaluated 1-year prepregnancy, during pregnancy, during puerperium (6 weeks postpregnancy), and 1-year postpregnancy. Relapse was defined as MS-related ho...
6 CitationsSource
Source
#1James D. BowenH-Index: 51
#2Chris M. KozmaH-Index: 19
Last.Amy L. Phillips (Merck Serono)H-Index: 9
view all 4 authors...
BackgroundAdministrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings.ObjectiveTo evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide).MethodsPatients from an administrative claims database (1 Jan 2012–31 Dec 2015) were selected if they: were 18–63...
1 CitationsSource
#1Natalie C. EdwardsH-Index: 3
#2Michael MunsellH-Index: 6
Last.Amy L. Phillips (Merck Serono)H-Index: 9
view all 4 authors...
AbstractObjective: To examine the time to first disease-modifying drug (DMD) treatment and to identify factors associated with early DMD initiation in newly-diagnosed patients with MS.Methods: This...
Source
#1Amy Perrin-Ross (LUC: Loyola University Chicago)
#2Chris M. KozmaH-Index: 19
Last.Amy L. Phillips (Merck Serono)H-Index: 9
view all 4 authors...
Objective: To evaluate the propensity for being highly adherent to subcutaneous interferon beta-1a (scIFNβ1a) versus dimethyl fumarate in patients with multiple sclerosis (MS). Background: Adherence to prescribed disease-modifying drug (DMD) treatment regimens is important for the optimization of patient care in MS. Design/Methods: Data from patients with MS were obtained from the US National Health and Wellness Survey or Lightspeed Research panel and its affiliates (eligible patients completed ...
6 CitationsSource
#1Michael MunsellH-Index: 6
#2Molly FreanH-Index: 3
Last.Amy L. Phillips (Merck Serono)H-Index: 9
view all 4 authors...
Abstract Background Administrative healthcare claims data provide a mechanism for assessing and monitoring multiple sclerosis (MS) disease status across large, clinically representative “real-world” populations. The estimation of MS disease status using administrative claims can be a challenge, however, due to a lack of detailed clinical information. Retrospective claims analyses in MS have traditionally used rates of MS relapses to approximate disease status. Healthcare costs may be alternate, ...
2 CitationsSource
1234567